{ "ok": true, "cik": "2030763", "ticker": "MEDS", "name": "DataMeds AI, Inc.", "filings": [ { "form": "8-K", "filed": "2026-09-17", "items": [ "8.01 Other Events" ], "url": "https://www.sec.gov/Archives/edgar/data/2030763/000149315226043169/0001493152-26-043169-index.htm" }, { "form": "8-K", "filed": "2026-09-16", "items": [ "1.01 Entry into a Material Definitive Agreement", "2.03 Creation of a Direct Financial Obligation", "3.02 Unregistered Sales of Equity Securities", "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/2030763/000149315226042951/0001493152-26-042951-index.htm" }, { "form": "8-K", "filed": "2026-08-18", "items": [ "2.02 Results of Operations and Financial Condition", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/2030763/000149315226038891/0001493152-26-038891-index.htm" }, { "form": "10-Q", "filed": "2026-08-17", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/2030763/000149315226038581/0001493152-26-038581-index.htm" }, { "form": "8-K", "filed": "2026-08-14", "items": [ "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/2030763/000149315226038475/0001493152-26-038475-index.htm" }, { "form": "S-1", "filed": "2026-08-07", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/2030763/000149315226036665/0001493152-26-036665-index.htm" } ], "events12m": 40, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0002030763.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=2030763" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets, no buy or sell views.", "edgar": "🫧 Edgar looked up DataMeds AI, Inc. ($MEDS). Last filing: 8-K (8.01 Other Events), 2026-09-17. 40 event filings (8-K) in the past twelve months. Auditor change (8-K Item 4.01) filed 2025-11-17.", "auditor": { "changes": [ { "filed": "2025-11-17", "url": "https://www.sec.gov/Archives/edgar/data/2030763/000149315225023918/0001493152-25-023918-index.htm" }, { "filed": "2025-07-08", "url": "https://www.sec.gov/Archives/edgar/data/2030763/000164117225018229/0001641172-25-018229-index.htm" } ], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2025-12-31", "revenue": 23337860, "revenueGrowth1y": 0.2873339709548839, "revenueGrowthPerYear": null, "yearsOfData": 2, "operatingMargin": -4.017039137264513, "operatingMarginPrior": -0.3389701189227259, "netMargin": -4.339495137943239, "operatingCashFlow": -10855029, "capitalSpending": null, "freeCashFlow": null, "researchAndDevelopment": null, "researchShareOfRevenue": null, "cash": 42571, "longTermDebt": 23487520, "longTermDebtChange": 0.004474166828145165, "revenueHistory": [ { "fiscalYearEnd": "2024-12-31", "revenue": 18128831 }, { "fiscalYearEnd": "2025-12-31", "revenue": 23337860 } ], "totalEquity": -12447801, "totalAssets": 30459449, "equityRatio": -0.40866796375732206, "returnOnEquity": null, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "range80": { "low": 22049012.708744895, "high": 39591482.41938142, "baseline": 30043619.987389147, "n": 749, "band": "b00" }, "ifPaceHeld": { "low": 22049012.708744895, "high": 39591482.41938142 } }, "edgarette": "🔖 Exposure: revenue $23.3M (FY2025), total debt $23.5M. Experience: revenue up 28.7% on the year; operating margin -401.7%, down from -33.9%. Soundness: equity -40.9% of assets (liabilities exceed assets). Credibility: 2 audited years, moderate weight. Range: 80% of past cases like this landed between $22.0M and $39.6M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A range, not a forecast. Against peers (30 filers, $50M+ revenue, its industry group): operating margin -401.7% against a 1.4% median; growth 28.7% against 0.9%.", "peers": { "sic": 5122, "sicDescription": "Wholesale-Drugs, Proprietaries & Druggists' Sundries", "calendarYear": 2025, "minRevenue": 50000000, "depth": 2, "group": "51", "growth": [ 0.0089, 31 ], "opMargin": [ 0.014, 30 ], "equityRatio": [ 0.2989, 28 ], "returnOnEquity": [ -0.0465, 21 ], "payoutRatio": [ 0.2988, 10 ] }, "summary": "DataMeds AI (MEDS) grew revenue 28.7% in FY2025 to $23 million, operating margin -402% against a 1.4% median for wholesale-drugs, proprietaries & druggists' sundries, equity -40.9% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
DataMeds AI, Inc. against its own record and its peers
Operating marginPeer median 1.4%-401.7%Revenue, on the yearPeer median 0.9%28.7%Equity of assetsPeer median 29.9%-40.9%Gold tick: the median of 28–28 peers with $50M+ revenue in wholesale-drugs, proprietaries & druggists' sundries
", "chartHorizon": null, "backtest": { "tests": 0, "hits": 0, "rate": null, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "registry": { "logged": "2026-09-20T14:27:01.681Z", "hash": "a5a55356f9b68712", "status": "open" }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "DataMeds AI (MEDS) grew revenue 28.7% in FY2025 to $23 million, operating margin -402% against a 1.4% median for wholesale-drugs, proprietaries & druggists' sundries, equity -40.9% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2025-12-31", "revenue": 23337860, "totalDebt": 23487520, "cash": 42571 }, "experience": { "revenueGrowth1y": 0.2873339709548839, "revenueGrowthPerYear": null, "operatingMargin": -4.017039137264513, "operatingMarginPrior": -0.3389701189227259, "netMargin": -4.339495137943239, "freeCashFlow": null }, "soundness": { "equityRatio": -0.40866796375732206, "returnOnEquity": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 5122, "sicDescription": "Wholesale-Drugs, Proprietaries & Druggists' Sundries", "calendarYear": 2025, "minRevenue": 50000000, "depth": 2, "group": "51", "growth": [ 0.0089, 31 ], "opMargin": [ 0.014, 30 ], "equityRatio": [ 0.2989, 28 ], "returnOnEquity": [ -0.0465, 21 ], "payoutRatio": [ 0.2988, 10 ] }, "credibility": { "auditedYears": 2, "weight": "moderate", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": { "filed": "2025-11-17", "url": "https://www.sec.gov/Archives/edgar/data/2030763/000149315225023918/0001493152-25-023918-index.htm" } }, "range": { "low": 22049012.708744895, "high": 39591482.41938142, "baseline": 30043619.987389147, "coverage": 0.8, "method": "v3", "basis": "next fiscal year revenue: baseline = revenue x (1 + mean of one-year and three-year pace); range = 10th to 90th percentile of how SEC company-years of the same size band actually turned out", "calibratedOn": { "companyYears": 749, "sizeBand": "b00" }, "kind": "a calibrated range, not a forecast; no view on the share price", "track": { "backtest": { "tests": 0, "hits": 0, "rate": null, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "registry": { "logged": "2026-09-20T14:27:01.681Z", "hash": "a5a55356f9b68712", "status": "open" }, "scorecard": "https://www.pops4.com/boards/scorecard" } }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0002030763.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=2030763" } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same if-the-pace-held arithmetic applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so." } }